Literature DB >> 24129557

Causes and consequences of lipoprotein(a) abnormalities in kidney disease.

Florian Kronenberg1.   

Abstract

Lipoprotein(a) is one of the strongest genetically determined risk factors for cardiovascular disease, and patients with chronic kidney disease have major disturbances in lipoprotein(a) metabolism. Concentrations are increased and are influenced by glomerular filtration rate (GFR) and the amount of proteinuria. The reason for this elevation can be increased synthesis, as is the case for patients with nephrotic syndrome or those treated by peritoneal dialysis. In hemodialysis patients, a catabolic block is the reason for this elevation. The elevated concentrations might contribute to the tremendous cardiovascular risk in this particular population. In particular, the genetically determined small apolipoprotein(a) isoforms are associated with an increased risk for cardiovascular events and total mortality.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24129557     DOI: 10.1007/s10157-013-0875-8

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  35 in total

1.  Urinary excretion of apo(a) fragments. Role in apo(a) catabolism.

Authors:  K M Kostner; G Maurer; K Huber; T Stefenelli; H Dieplinger; E Steyrer; G M Kostner
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-08       Impact factor: 8.311

2.  Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation.

Authors:  F Kronenberg; E Trenkwalder; A Lingenhel; G Friedrich; K Lhotta; M Schober; N Moes; P König; G Utermann; H Dieplinger
Journal:  J Lipid Res       Date:  1997-09       Impact factor: 5.922

3.  The mysterious lipoprotein(a) is still good for a surprise.

Authors:  Claudia Lamina; Florian Kronenberg
Journal:  Lancet Diabetes Endocrinol       Date:  2013-08-27       Impact factor: 32.069

4.  High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients.

Authors:  J Craig Longenecker; Michael J Klag; Santica M Marcovina; Yong-Mei Liu; Bernard G Jaar; Neil R Powe; Nancy E Fink; Andrew S Levey; Josef Coresh
Journal:  J Am Soc Nephrol       Date:  2005-03-30       Impact factor: 10.121

5.  Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up.

Authors:  L Kerschdorfer; P König; U Neyer; C Bösmüller; K Lhotta; M Auinger; M Hohenegger; P Riegler; R Margreiter; G Utermann; H Dieplinger; F Kronenberg
Journal:  Atherosclerosis       Date:  1999-06       Impact factor: 5.162

6.  Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study.

Authors:  J Craig Longenecker; Michael J Klag; Santica M Marcovina; Neil R Powe; Nancy E Fink; Federico Giaculli; Josef Coresh
Journal:  Circulation       Date:  2002-11-26       Impact factor: 29.690

7.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.

Authors:  J Zimmermann; S Herrlinger; A Pruy; T Metzger; C Wanner
Journal:  Kidney Int       Date:  1999-02       Impact factor: 10.612

8.  Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis.

Authors:  F Kronenberg; P König; U Neyer; M Auinger; A Pribasnig; U Lang; J Reitinger; G Pinter; G Utermann; H Dieplinger
Journal:  J Am Soc Nephrol       Date:  1995-07       Impact factor: 10.121

9.  Apo(a) isoforms predict risk for coronary heart disease. A study in six populations.

Authors:  C Sandholzer; N Saha; J D Kark; A Rees; W Jaross; H Dieplinger; F Hoppichler; E Boerwinkle; G Utermann
Journal:  Arterioscler Thromb       Date:  1992-10

10.  Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.

Authors:  Stefan Kiechl; Johann Willeit; Manuel Mayr; Brigitte Viehweider; Martin Oberhollenzer; Florian Kronenberg; Christian J Wiedermann; Sabine Oberthaler; Qingbo Xu; Joseph L Witztum; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-05-31       Impact factor: 8.311

View more
  19 in total

Review 1.  PCSK9 in chronic kidney disease.

Authors:  P Pavlakou; E Liberopoulos; E Dounousi; M Elisaf
Journal:  Int Urol Nephrol       Date:  2017-01-13       Impact factor: 2.370

Review 2.  Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.

Authors:  Alan Chait; Ira Goldberg
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

Review 3.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

4.  Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort).

Authors:  Archna Bajaj; Scott M Damrauer; Amanda H Anderson; Dawei Xie; Matthew J Budoff; Alan S Go; Jiang He; James P Lash; Akinlolu Ojo; Wendy S Post; Mahboob Rahman; Muredach P Reilly; Danish Saleheen; Raymond R Townsend; Jinbo Chen; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-24       Impact factor: 8.311

Review 5.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

Review 6.  Cardiovascular risk factors in children on dialysis: an update.

Authors:  Uwe Querfeld; Franz Schaefer
Journal:  Pediatr Nephrol       Date:  2018-10-31       Impact factor: 3.714

Review 7.  Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy.

Authors:  Anne Langsted; Børge G Nordestgaard
Journal:  Curr Atheroscler Rep       Date:  2021-06-20       Impact factor: 5.113

8.  Lipid status association with 25-hydroxy vitamin D: Cross sectional study of end stage renal disease patients.

Authors:  Neda Milinković; Marija Sarić; Snežana Jovičić; Duško Mirković; Višnja Ležaić; Svetlana Ignjatović
Journal:  J Med Biochem       Date:  2020-09-02       Impact factor: 3.402

Review 9.  Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins.

Authors:  Nans Florens; Catherine Calzada; Egor Lyasko; Laurent Juillard; Christophe O Soulage
Journal:  Toxins (Basel)       Date:  2016-12-16       Impact factor: 4.546

Review 10.  The Role of Emerging Risk Factors in Cardiovascular Outcomes.

Authors:  Ben Lacey; William G Herrington; David Preiss; Sarah Lewington; Jane Armitage
Journal:  Curr Atheroscler Rep       Date:  2017-06       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.